Skip to main content

Table 1 Baseline characteristics of patients on NVP and EFV by study design

From: Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies

Author

Country

Design

Sample size

Follow-up Period

Female

Age

Median ± IQR

CD4 count

Median ± IQR

Viral load (log)

Median ± IQR

BMI

Median ± IQR

Stringer et al. [50]

Zambia and Kenya

Prospective Cohort

509

152

4 years

661

Zambia 32 (28–36)

Kenya 32 (28–36)

148 (88–211)

147 (76.5–212.5)

5.0 (4.4–5.4)

5.3 (4.8–5.9)

19.7 (18.3–21.9)

19.9 (17.7–22.6)

Kwobah et al. [51]

Kenya

Case-control

3233

5 years

1992

Case: 36.3(30.6–43.2)

Control:

36.5(30.7–43.1)

Case: 80 (32–177)

Control: 194 (112–324)

NA

NA

Nachega et al. [45]

South Africa

Cohort

1817

10 years

1771

NVP: 33.2 (7.68)

EFV: 36(8.0)

NVP: 171(78–243)

EFV: 136(58–216)

NVP: 5.1(4.6–5.6)

EFV: 5.2(4.7–5.7)

NA

Boulle et al. (18, 48)

South Africa

Cohort

2679

4 years

1896

32(28–38)

83(34–140)

5.5(4.6–5.5)

NA

Shearer et al. ([47])

South Africa

Cohort

12,840

8 years

7962

EFV: 37.2(31.9–43.9)

NVP: 33.0(28.4–39.1)

EFV: 98(36–169)

NVP: 100.5(42–160)

NA

EFV: 21.7 (19.2_24.9)

NVP: 22.0 (19.7_25.1)

Sarfo et al. [52]

Ghana

Retrospective Observational

3990

7 years

2717

EFV: 40 (35–47)

NVP: 35 (30–41)

EFV: 127 (45–213)

NVP: 140 (56–220)

NA

EFV: 19.6 (17.4–22.3)

NVP: 19.9 (17.6–22.9)

Shearer et al. [46]

South Africa

Cohort

2385

1 year

1485

EFV: 37.8 (31.8–44.3)

NVP: 33.1 (28.1–40.4)

EFV: 132 (58–194)

NVP: 132 (66–179)

NA

EFV: 22.5 (19.7–25.9)

NVP: 23.0 (20.2–25.6)

Barth et al. [49]

South Africa

Retrospective observational cohort

735

2–4 years

526

Mean = 35.3

68 (20–140)

Mean = 4.9

NA

Gsponer et al. [54]

Sub-Saharan Africa

Collaborative analysis

2404

6 years

1276

Switched: 29 (25–33)

Not switched: 29 (25–34)

Switched: 77 (41–133)

Not switched: 146 (82–232)

NA

NA

Sarfo et al. [10]

Ghana

Retrospective cohort study

3999

7 years

2727

38 (32–45)

132 (50–217)

NA

19.8(17.5–22.7)

Keiser et al. [55]

Sub-Saharan Africa

Case control

4281

5 years

3022

Switch: 35 (30–41)

Not switch: 34 (30–40)

Switch: 73 (23–133)

Not switch: 67 (21–161)

Switch: 5.0 (4.4–5.6)

Not switch: 5.3 (4.6–5.8)

NA

Anlay et al. [53]

Ethiopia

Retrospective follow-up

410

5 years

265

33.3 ± 8.7

162.5 (90.5–235.5)

NA

NA

van Zyl et al. [43]

South Africa

Retrospective

167

4 years

NA

NA

NA

NA

NA

Abah et al. [42]

Nigeria

Cohort

6309

3 years

4156

35 (30–42)

154 (76–259)

NA

NA

Bock et al. [44]

South Africa

Multicentre cohort

27,350

4 years

16,828

EFV: 35.8 (30.7–42.6)

NVP: 31.1 (27.1–35.8)

EFV: 107 (51–160)

NVP: 132 (76–177)

NA

NA

Tirfe et al. [25]

Ethiopia

Retrospective cohort study

492

3 years

289

EFV: 35(10)

NVP: 33(11)

NA

NA

NA

  1. NA=Not Applicable